Bristol Myers Squibb has announced the presentation of new data from its targeted protein degradation platform at the 2025 European Hematology Association (EHA) Annual Congress, scheduled from June 12-15 in Milan, Italy. The presentations will feature updated clinical findings on the company's investigational oral CELMoD™ agents, including mezigdomide and iberdomide for multiple myeloma, and golcadomide for non-Hodgkin lymphoma. Additionally, the first results evaluating the company's first-in-class, oral BCL6 ligand-directed degrader (BMS-986458) in non-Hodgkin lymphoma will be presented. These developments highlight Bristol Myers Squibb's ongoing commitment to advancing targeted protein degradation therapies in cancer treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.